Taken together, our findings not only demonstrate the possibility of inhibiting FXR1 in TP53 and FXR2 homozygous co-deletion cancers as a potential treatment option, but also reveal the novel role of FXR1 in gene transcription. This evidence concerns the gene FXR2 and cancer.